Join Now

Author Archives: admin

bioMérieux receives U.S. FDA 510(k) clearance and CLIA-waiver for Anterior Nasal Swab specimens, an additional sample type for use with the BIOFIRE® SPOTFIRE® R/ST Panel Mini

Marcy-l’Étoile (France), August 18, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for the addition of Anterior Nasal Swab (ANS) as a […]

Posted in BioUtah News | Comments Off on bioMérieux receives U.S. FDA 510(k) clearance and CLIA-waiver for Anterior Nasal Swab specimens, an additional sample type for use with the BIOFIRE® SPOTFIRE® R/ST Panel Mini

EDWARDS LIFESCIENCES ANNOUNCES $500 MILLION ACCELERATED SHARE REPURCHASE

IRVINE, Calif.–(BUSINESS WIRE)– Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement (“ASR”) to repurchase $500 million of Edwards’ common stock. With this transaction, Edwards has repurchased more than $800 million of shares in 2025. Under the terms of this ASR, Edwards will receive an initial delivery of approximately […]

Posted in Policy News | Comments Off on EDWARDS LIFESCIENCES ANNOUNCES $500 MILLION ACCELERATED SHARE REPURCHASE

Nusano Cuts Ribbon on State-of-the-Art Radioisotope Production Facility

WEST VALLEY CITY, Utah – Aug. 21, 2025 – Nusano, a physics company transforming the production of radioisotopes, today cut the ribbon on its 190,000-square-foot radioisotope production facility. The site will be capable of producing more than 40 different radioisotopes for use in cancer diagnostics and therapeutics, as well as industrial applications, such as long-lived […]

Posted in BioUtah News | Comments Off on Nusano Cuts Ribbon on State-of-the-Art Radioisotope Production Facility

Sethera Therapeutics Unveils Breakthrough Enzymatic Platform for Next-Generation Peptide Drugs

SALT LAKE CITY, Utah August 21, 2025 — Sethera Therapeutics today announced publication in the Proceedings of the National Academy of Sciences (PNAS) of peer-reviewed results describing an enzymatic crosslinking platform that forges durable thioether “staples,” locking peptides into drug-like cyclic architectures. The platform works across a broad range of substrates, including sequences built entirely […]

Posted in BioUtah News | Comments Off on Sethera Therapeutics Unveils Breakthrough Enzymatic Platform for Next-Generation Peptide Drugs

Webinar Recap: Immigration Compliance Under Pressure

As immigration enforcement and workplace inspections intensify under the current administration, companies in the life sciences sector, particularly those with manufacturing operations, must be proactive in strengthening compliance. Presented by Ogletree Deakin’s Kathleen Weron on July 1, 2025, this webinar provided an overview of the essential components of I-9 compliance, strategies for responding to audits, […]

Posted in Policy News | Comments Off on Webinar Recap: Immigration Compliance Under Pressure

2025 BIO International Recap

BioUtah and its Utah consortium made their mark this week at the BIO International Conference, hosting a Utah Pavillion to promote the state’s fast-growing life sciences industry. The conference, held in Boston, MA. drew appproximately 20,000 attendees. The Utah delegation included BioUtah, Utah life sciences companies, the Governor’s Office of Economic Development, the Unversity of […]

Posted in Policy News | Comments Off on 2025 BIO International Recap

Merit Medical Acquires Biolife Delaware

Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports. Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profile Merit reaffirms full-year 2025 […]

Posted in BioUtah News | Comments Off on Merit Medical Acquires Biolife Delaware

BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies

New BD FACSDiscover™ A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma

Posted in BioUtah News | Tagged | Comments Off on BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies

KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging

Visit ISMRM Booth H19 for Hands-On Demonstrations of the KyphoLift™ and KyphoWedge™ Systems

Posted in BioUtah News | Tagged | Comments Off on KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging

Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills

BioUtah president and CEO, Kelvyn Cullmore, recently penned an op-ed published in the Deseret News.

Posted in BioUtah News | Tagged | Comments Off on Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis

The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.

Posted in BioUtah News | Tagged | Comments Off on Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial

In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months.

Posted in BioUtah News | Tagged | Comments Off on Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial